Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000380012 | SCV000344795 | uncertain significance | not provided | 2017-12-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001859712 | SCV002197101 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2P; Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9 | 2021-05-03 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with DAG1-related conditions. ClinVar contains an entry for this variant (Variation ID: 290274). This variant is present in population databases (rs759029561, ExAC 0.005%). This sequence change replaces glutamic acid with lysine at codon 592 of the DAG1 protein (p.Glu592Lys). The glutamic acid residue is moderately conserved and there is a small physicochemical difference between glutamic acid and lysine. |
Revvity Omics, |
RCV000380012 | SCV003834220 | uncertain significance | not provided | 2019-08-09 | criteria provided, single submitter | clinical testing |